Effect of Camellia japonica oil on human type I procollagen production and skin barrier function.
Type I collagen is the primary component of the skin dermis. Both the quantity and quality of extracellular collagen are primarily related to skin ageing. In this study, we investigated the possibility that Camellia japonica oil (CJ oil) may be introduced as an anit-wrinkle agent. As a first step to this end, human COL1A2 promoter luciferase assay was performed in human dermal fibroblast cells. CJ oil was determined to activate human COL1A2 promoter in a concentration-dependent manner. In consistency with this result, while matrix metalloproteinase (MMP)-1 activity was inhibited by CJ oil, human type I procollagen synthesis was also induced by CJ oil. These results suggest the possibility that CJ oil may be involved in the skin ageing. For the evaluation of CJ oil's safety and efficiency on human skin, human skin primary irritation test and trans-epidermal water loss (TEWL) were performed. Transepidermal water loss (TEWL) was measured before treatment then, 1h and 2h after treatment; the forearm site was selected to measure TEWL. Also, a human skin primary irritation test was performed on the normal skin (upper back) in 30 volunteers to see if a certain material included in CJ oil has irritation or sensitization potential. In these assays, CJ oil reduced trans-epidermal water loss (TEWL) and did not induce any adverse reactions. Therefore, based on these results, we suggest the possibility that CJ oil may be considered as possible wrinkle-reducing candidates for topical application.
Jung
Eunsun
E
Biospectrum Life Science Institute, 101-701 SK VENTIUM, 522 Dangjung Dong, Gunpo City, 435-833 Gyunggi Do, Republic of Korea.
Lee
Jongsung
J
Baek
Jihoon
J
Jung
Kwangsun
K
Lee
Jiyoung
J
Huh
Sungran
S
Kim
Saebom
S
Koh
Jaesook
J
Park
Deokhoon
D
D000328:Adult; D028244:Camellia; D003094:Collagen / Q000096:biosynthesis* / Q000235:genetics; D024042:Collagen Type I / Q000096:biosynthesis* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D020781:Matrix Metalloproteinase 1 / Q000096:biosynthesis; D010938:Plant Oils / Q000009:adverse effects / Q000494:pharmacology*; D011401:Promoter Regions, Genetic; D012867:Skin / Q000187:drug effects* / Q000378:metabolism; D015595:Skin Aging / Q000187:drug effects; D023422:Skin Irritancy Tests; D014162:Transfection; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014870:Water Loss, Insensible / Q000187:drug effects
D024042:Collagen Type I; D010938:Plant Oils; D014409:Tumor Necrosis Factor-alpha; D003094:Collagen; D020781:Matrix Metalloproteinase 1